Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker LXRX
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 5, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 6, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 7, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 6, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 6, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| May 6, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| May 6, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Apr 30, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 30, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Apr 30, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Apr 30, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 5, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 2, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 2, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Feb 2, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Feb 2, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Feb 2, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Jan 29, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jan 29, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jan 29, 2026 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 10, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 6, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 6, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 6, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 28, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jul 3, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Jun 3, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 3, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 13, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 28, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Mar 6, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 7, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule | 8-K | 8-K ↗ |
| Jan 2, 2025 | LXRX Lexicon Pharmaceuticals, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 22, 2024 | LXRX Lexicon Pharmaceuticals, Inc. | 2.05 Costs Associated with Exit or Disposal Activities | 8-K | 8-K ↗ |
| Nov 20, 2024 | LXRX Lexicon Pharmaceuticals, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 12, 2024 | LXRX Lexicon Pharmaceuticals, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
36 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:38 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances